Evidence map›Paper›PMID 39046666›Full record

ReviewCurrent rheumatology reports2024

Updates in diagnosis and treatment of pediatric antiphospholipid syndrome.

Lucia M Campos, Paula S Marra, Clara R Doria, Sebastian D Cordoba, Clovis A Silva

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lucia M CamposPediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Instituto da Criança e do Adolescente, Hospital das Clinicas FMUSP, Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo, SP, 05403-000, Brazil. lucia@arrudacampos.com.
Paula S MarraPediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Instituto da Criança e do Adolescente, Hospital das Clinicas FMUSP, Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo, SP, 05403-000, Brazil.
Clara R DoriaPediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Instituto da Criança e do Adolescente, Hospital das Clinicas FMUSP, Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo, SP, 05403-000, Brazil.
Sebastian D CordobaPediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Instituto da Criança e do Adolescente, Hospital das Clinicas FMUSP, Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo, SP, 05403-000, Brazil.
Clovis A SilvaPediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Instituto da Criança e do Adolescente, Hospital das Clinicas FMUSP, Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo, SP, 05403-000, Brazil.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 304984/2020-5 to CASFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2015/03756-4 to CAS
6 · The paper itself

Abstract

purpose of reviewThis review offers an overview of the most important recent articles on pediatric APS. RECENT

findingsNon-thrombotic extra criteria manifestations were prevalent in pediatric APS. Pregnancy morbidity has been described as the first manifestation of APS at youth age, impairing gestational outcomes. The 2023 APS criteria were developed for adult APS patients, and there is still a lack of pediatric-specific APS criteria. Catastrophic APS was more commonly reported as the initial manifestation of pediatric APS than in adults. Regarding treatment, direct oral anticoagulants have been recently approval for pediatric patients with venous thrombosis. New approaches have been proposed for severe cases, for arterial thrombosis, and rituximab for refractory cases. Recurrences typically occurred early and were associated with older age at diagnosis. Current studies highlighted the multifaceted nature of pediatric APS. Further large prospective multicenter studies evaluating new medications capable of reducing recurrence risk and improving prognosis in this population will be required.

Indexed as

Antiphospholipid SyndromeAnticoagulantsChildFemaleHumansPregnancyRituximabAnticoagulantsRituximabAntiphospholipid syndromeChildhoodClassification criteriaPrognosisSystemic Lupus ErythematosusTreatment

Identifiers

PMID39046666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.